# Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA

> **NCT06307249** · PHASE1 · RECRUITING · sponsor: **Lebanese University** · enrollment: 50 (estimated)

## Conditions studied

- Cancer
- Solid Tumor
- Colorectal Cancer
- Breast Cancer
- Ovarian Cancer
- Lung Cancer
- Targeted Therapy
- Chemotherapy
- Immunotherapy
- Precision Therapy

## Interventions

- **GENETIC:** SNP
- **DRUG:** Palbociclib 125mg
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06307249
- **Lead sponsor:** Lebanese University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-15
- **Primary completion:** 2025-12
- **Final completion:** 2027-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06307249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06307249, "Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06307249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*